Anonymous Data Sharing for Small Bowel
Launched by UNIVERSITY COLLEGE, LONDON · Mar 4, 2025
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving how we assess small bowel diseases, particularly Crohn's disease, using magnetic resonance imaging (MRI). Crohn's disease can cause various issues in the bowel, and MRI is a safe and effective way to examine these problems without using radiation. Currently, radiologists have to manually measure important features on the MRI scans, which can be time-consuming and challenging. This trial aims to develop a computer program that can quickly and accurately analyze MRI images, helping doctors make better decisions for patient care.
To create this software, the researchers are looking for participants who had a small bowel MRI at University College London Hospitals (UCLH) between 2005 and September 2010. Eligible participants include those with a normal MRI result and no signs of bowel disease based on other tests. Those who are younger than 16 or do not meet the criteria will not be included. If you or a family member qualifies, participating in this study could help advance medical technology and improve the diagnosis and treatment of small bowel diseases in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Had a small bowel MRI at UCLH between 2005 and Sept 2010 as part of routine clinical practice who:
- • Have a clinical standard of reference within 6 weeks of the MRI scan
- • Patients with normal small bowel MRI studies and no clinical evidence of bowel pathology on any additional diagnostic investigations
- Exclusion Criteria:
- • Patients \<16 or not fulfilling either inclusion criteria
About University College, London
University College London (UCL) is a leading global research institution renowned for its commitment to advancing healthcare through innovative clinical trials. As a prominent sponsor of clinical research, UCL leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous investigations aimed at improving patient outcomes and addressing pressing medical challenges. The institution fosters collaboration among researchers, healthcare professionals, and industry partners, ensuring that its trials adhere to the highest ethical standards and regulatory guidelines. UCL's dedication to translating scientific discoveries into practical applications underscores its role as a vital contributor to the advancement of medical science and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Stuart Taylor
Principal Investigator
University College, London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported